
ONCY Stock Forecast & Price Target
ONCY Analyst Ratings
Bulls say
Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapeutics, particularly highlighting its lead product, pelareorep, which enhances the immune system's capability to combat cancer and may become a foundational immunotherapy for specific breast cancer types. The potential for strategic partnerships is significant, as such collaborations could extend the company's operational runway and enable the progression of pelareorep towards regulatory approval, thereby unlocking substantial value for shareholders. Additionally, external validation from key opinion leaders reinforces Oncolytics’ reputation and strengthens its position to secure these partnerships, enhancing the overall outlook for the company's future growth and market presence.
Bears say
Oncolytics Biotech Inc. is in the clinical-stage of its biopharmaceutical development, focusing on treatments for various cancers but currently lacks proven revenue-generating products, which raises concerns about its financial stability. The company’s pipeline consists primarily of experimental therapies, with the lengthy development timelines and inherent risks associated with clinical trials contributing to its uncertainty in achieving successful outcomes. Additionally, recent financial reports indicate rising operational costs without offsetting revenues, leading to concerns about Oncolytics Biotech's ability to sustain its operations and funding for ongoing projects.
This aggregate rating is based on analysts' research of Oncolytics Biotech, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ONCY Analyst Forecast & Price Prediction
Start investing in ONCY
Order type
Buy in
Order amount
Est. shares
0 shares